Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Top 3 Hep C Studies for Primary Care
Highlights of 3 studies from 2017 that support the role of PCPs in HCV infection treatment, including prescribing direct-acting antiviral agents.
Three recent studies show the value of using direct-acting antiviral (DAA) agents to treat patients infected with hepatitis C virus (HCV), including treatment by primary care physicians:Â The majority of patients infected with HCV can be safely, effectively managed in a primary care setting.HCV viral load after four weeks of treatment with DAAs predicts sustained virologic response (SVR) in a real-world clinical setting.DAA therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney diseaseÂ
Related Videos
Related Content
